The Second Wave in Kinase Cancer Drugs  

Oleh:

Garber, Ken

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 24 no. 2 (Feb. 2006), page 127-130.
Topik: DRUG; kinase; cancer drugs

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.4 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Cancer drug targeting signaling pathways have been hampered by problems of efficacy and tumor resistance. Will the next generation of kinase inhibitors fare better than the first? Ken Garebr investigates. When the US Food and Drug Association (FDA) gave its blessing in december to nexavar (sorafenib), from onyx harmaceuticals in emeryville, california, it marked the fifth drug approval of a protein kinase inhibitor in the last four years for treating cancer. And the pace is quickening. Two more companies are awaiting almost certain FDA approval for their kinase inhibitores (table 1) and at lease 40 are in clinical trials, making kinases the seconf most popular frug target class in the pharmaceutical and biotech industries, after G-Protein coupled receptors...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali